You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
雅培大削新冠检测收入预测 股价挫逾9%
阿思达克 06-02 09:04
美国雅培药厂(Abbott)(ABT.US)更新全年度财务展望,预期业绩受新冠疫苗接种加快导致相关检测收入减少影响。公司表示,美国及其他主要已发展国家新冠确诊显着减少,全球加快疫苗推出及美国当局放宽已接种疫苗人士检测规定,均影响旗下新冠检测产品需求。

公司去年从新冠检测录得逾30亿元收入,今年首季新冠检测收入中,逾半来自海外市场。但公司预期美国及海外检测需求将下跌,全年度新冠检测收入料介乎40亿至45亿美元,低於早前预测的65亿至70亿美元。全年度每股经调整溢利料介乎4.3至4.5美元,低於早前预测的最少5美元及市场预测的5.04美元。

雅培股价昨日(1日)跌9.3%,报105.79美元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account